intermediate filament family orphan 1Genealiases: HOM-TES-103 · IFFO
Q-omics provides the consensus-scored IFFO1 profile across patient tissues and cancer cell-line models. IFFO1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IFFO1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, IFFO1 RNA expression shows 22,952 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where IFFO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFFO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFFO1 survival associations across molecular data types. IFFO1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFFO1 RNA expression–survival associations across cancer types. High IFFO1 expression shows unfavorable associations in KIRC, UVM and LGG, but favorable associations in HNSC, PAAD and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IFFO1 RNA expression.
This table summarizes IFFO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IFFO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFFO1 shows lower tumor expression in BLCA, LUSC and LUAD and higher tumor expression in KIRC, LIHC and KIRP. The KIRC box plot shows higher IFFO1 RNA expression in tumor versus normal tissue (log2 FC = +1.539, t-test p < 0.001).
This table shows molecular features associated with IFFO1 in patient tissues and cancer cell lines. In patient samples, IFFO1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFFO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
